New immune therapy aims to save lives in severe pneumonia
NCT ID NCT07492875
First seen Apr 08, 2026 · Last updated Apr 29, 2026 · Updated 3 times
Summary
This study tests whether adding an experimental drug (nogapendekin alfa inbakicept) and special immune cells (iNKT cells) to standard care can lower the death rate in critically ill adults with severe pneumonia, often complicated by sepsis or lung failure. About 10 participants in the ICU will receive either the new treatment or a placebo, and researchers will track survival and recovery over 28 days. The goal is to see if this approach can help the body fight infection better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.